Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting
Nurix Therapeutics presented new preclinical and Phase 1 data for its BTK degrader bexobrutideg (NX-5948) in chronic spontaneous urticaria (CSU) at the Society for Investigative Dermatology Annual Meeting. The data showed that bexobrutideg achieves virtually complete BTK degradation in blood and skin of healthy volunteers, demonstrating a ~25-fold potency advantage over the BTK inhibitor remibrutinib in preclinical models.
Key figures
- Drug Name
- bexobrutideg (NX-5948)
- Phase Of Trial
- Phase 1
- Potency vs remibrutinib
- ~25-fold greater
- Proteomic analysis count
- 8,700 proteins
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.